Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,225.04 +2.36 (+0.05%) Dow
39,510.10 -2.74 (-0.01%) Nasdaq
16,391.90 +51.04 (+0.31%) Bitcoin USD
63,041.24 +1,676.66 (+2.73%) CMC Crypto 200
1,298.03 +37.83 (+3.00%)
NVO Jan 2026 57.500 call
| Previous close | 83.50 |
| Open | 83.50 |
| Bid | 71.00 |
| Ask | 76.00 |
| Strike | 57.50 |
| Expiry date | 2026-01-16 |
| Day's range | 83.50 - 83.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- Reuters
UPDATE 2-Denmark faces Wegovy shortage due to rising demand
Denmark faces a supply shortage for two doses of Novo Nordisk's Wegovy weight-loss drug in the coming months due to rising demand, the Danish Medicines Agency said on Monday. The hugely popular Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
The Telegraph‘Outrageously’ expensive Ozempic should be cheaper, says Bernie Sanders
Ozempic and Wegovy maker Novo Nordisk should be forced to cut the price of its obesity and diabetes wonder drugs, Bernie Sanders has said, claiming the current costs are “outrageously high”.
Barrons.comNovo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster
The company will collaborate with a biotech founded by Flagship Pioneering, the venture capital firm that created Moderna.
